How do I order a quantitative serum screen for oral hypoglycemic agents for suspected drug‑induced hypoglycemia?

How to Order a Screen for Oral Hypoglycemic Agents

Order a quantitative serum or urine screen for oral hypoglycemic agents during documented hypoglycemia (plasma glucose <60 mg/dL), ideally at the end of a supervised 72-hour fast or during a spontaneous hypoglycemic episode when plasma glucose, insulin, C-peptide, proinsulin, and β-hydroxybutyrate are simultaneously collected. 1

When to Order the Screen

The Endocrine Society guidelines specify precise timing for oral hypoglycemic agent screening:

• During spontaneous hypoglycemia: If you can capture a spontaneous episode with documented low plasma glucose (<55 mg/dL with symptoms), collect the screen at that time 1

• At the end of a supervised 72-hour fast: When plasma glucose falls below 45 mg/dL with symptoms (or <55 mg/dL if Whipple's triad was previously documented), collect samples for plasma glucose, insulin, C-peptide, proinsulin, β-hydroxybutyrate, and oral hypoglycemic agents before administering treatment 1

• During a mixed-meal test: If postprandial hypoglycemia is suspected and Whipple's triad is demonstrated (plasma glucose <60 mg/dL), obtain a sample for oral hypoglycemic agents 1

What to Order Specifically

The screen should detect multiple drug classes using LC-MS/MS methodology:

First-Generation Sulfonylureas

• Chlorpropamide
• Tolazamide
• Tolbutamide

Second-Generation Sulfonylureas

• Glimepiride
• Glipizide
• Glyburide (glibenclamide)
• Gliclazide

Meglitinides

• Repaglinide
• Nateglinide

Thiazolidinediones

• Rosiglitazone
• Pioglitazone

2, 3, 4

Sample Type and Collection

• Serum/plasma is the standard specimen for quantitative detection 5, 2
• Urine can be used as an alternative, particularly for broader screening that includes metabolites 4
• Collect samples before administering any treatment for hypoglycemia to avoid false negatives 1

Critical Context for Ordering

This test is part of the comprehensive hypoglycemia workup in patients without diabetes who present with unexplained hypoglycemia. The complete panel at the time of hypoglycemia should include:

1. Plasma glucose (laboratory-measured, not point-of-care)
2. Insulin
3. C-peptide
4. Proinsulin
5. β-hydroxybutyrate
6. Oral hypoglycemic agent screen
7. Insulin antibodies (can be measured separately, not necessarily during hypoglycemia)

1

Clinical Pitfalls to Avoid

Don't rely on point-of-care glucose monitors to determine when to collect samples—use laboratory-measured plasma glucose concentrations 1. Point-of-care devices lack precision at low glucose levels.

Don't wait for symptoms alone in patients with prior documented Whipple's triad—you can end the fast and collect samples at plasma glucose <55 mg/dL even without symptoms 1.

Consider factitious hypoglycemia in patients with:

• Medical background or spouse with diabetes
• Unusual psychiatric history or affect
• Abrupt onset of severe symptoms without preceding milder episodes
• Absent response to provocative testing

6, 7

Interpretation Framework

A negative screen in the setting of elevated insulin (≥3.0 µU/mL), C-peptide (≥0.6 ng/mL), and proinsulin (≥5.0 pmol/L) during hypoglycemia suggests endogenous hyperinsulinism (e.g., insulinoma) and warrants localization procedures 1.

A positive screen identifies exogenous oral hypoglycemic agent use (inadvertent, accidental substitution, or factitious) and eliminates the need to search for an insulinoma 6, 7.

The detection limits for modern LC-MS/MS methods are typically 5-100 ng/mL depending on the specific agent, which is adequate for clinical diagnosis 3.